Improve Research Reproducibility A Bio-protocol resource
Concise Method
tooltip

Xenograft tumors

SM Sankar N. Maity
MT Mark A. Titus
RG Revekka Gyftaki
GW Guanglin Wu
JL Jing-Fang Lu
SR S. Ramachandran
EL Elsa M. Li-Ning-Tapia
CL Christopher J. Logothetis
JA John C. Araujo
EE Eleni Efstathiou
request Request a Protocol
ask Ask a question
Favorite

MDA-PCa-133-4 (MDA-PCa-133) prostate cancer xenograft tumors were derived from bone lesions of a patient with CRPC as previously described28,29,30,31. Written informed consent had been obtained from the patient prior to sample acquisition, according to a protocol approved by the Institutional Review Board of The University of Texas MD Anderson Cancer Center. The xenograft tumors were initially maintained by serial passaging in noncastrated SCID mice. To develop castration-resistant xenograft tumors, 6- to 8-week-old male CB17 SCID mice (Charles River Laboratories International, Inc., Wilmington, MA) were surgically castrated under anesthesia, tumor pieces (about 20 to 30 mm2) were implanted subcutaneously in the flank 10 days postcastration, and the mice were monitored weekly for tumor growth. The xenograft tumors were then maintained by serial passaging in the castrate mice.

Copyright and License information:  ©2016, The Author(s)
This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A